This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In patients with obesity and heart failure with preservedejectionfraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.
Heart failure with preservedejectionfraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preservedejectionfraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′.
Background:Patients with heart failure (HF) with preservedejectionfraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 5.4,16.1), 8.1 2.7,13.4), 4.6 (-0.6,9.9)
The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. Patients studied were older (68 years old), white (90%), obese (average BMI 34 kg/m2) individuals with an average LVEF of 61%. Patients were divided into two groups based on BB use at trial enrollment.
Background: Patients with heart failure, a preservedejectionfraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. Circulation, Ahead of Print. The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio 1.63, 95%CI, 1.17, 2.28;P=0.004).Conclusions:
The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. HFpEF is HF with preservedejectionfraction in which pressure builds up in the heart and lungs due to a stiffened left ventricle.
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preservedejectionfraction and obesity.
What better way to join the fall festivities than by spotlighting key insights in cardiorenal metabolic medicine, primary prevention, and quality of life improvements shared at this year’s biggest U.S. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content